AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth and implants in patients with generalized chronic periodontitis (GCP)
Number of subjects: 39
Study 15857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth and implants in periodontally healthy patients
Number of subjects: 39
Study 12055814 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg
Number of subjects: 212
Study 12055814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 10606129 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based family nursing clinical rotations
Number of subjects: 137
Study 7567418 — intervention group
Group type: EXPERIMENTAL
Intervention: SHORT‐F condition
Number of subjects: 0
Study 7567418 — intervention group
Group type: EXPERIMENTAL
Intervention: LONG‐F condition
Number of subjects: 0
Study 7567418 — intervention group
Group type: EXPERIMENTAL
Intervention: Task repetition
Number of subjects: 0
Study 7567418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 0
Study 7567418 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle testing of 'Weak' or 'Strong'
Number of subjects: 0
Study 2031518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 231
Study 2031518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 231
Study 2031518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 231
Study 2031518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 231
Study 2031518 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 231
Study 7247083 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP card
Number of subjects: 24
Study 7247083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 30764560 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal (HP)
Number of subjects: 20
Study 30764560 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal (HCHO)
Number of subjects: 20
Study 30764560 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OB vs. HW
Number of subjects: 20
Study 29208251 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 75
Study 29208251 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 75
Study 25684087 — intervention group
Group type: EXPERIMENTAL
Intervention: Device servo‐regulated cooling
Number of subjects: 100
Study 25684087 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (control)
Number of subjects: 100
Study 25008206 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention (group- and home-based)
Number of subjects: 130
Study 25008206 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 130
Study 22390266 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐min intervention designed to reframe metacognitive interpretation of difficulty
Number of subjects: 310
Study 22390266 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 310
Study 19769793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified diet and physical activity
Number of subjects: 507
Study 19769793 — intervention group
Group type: COMPARATOR
Intervention: Conventional care control
Number of subjects: 507
Study 19769793 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploblock including variants rs659366, rs653529, rs15763, and rs1726745
Number of subjects: 507
Study 19769793 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype comprising alleles rs659366-G, rs653529-A, rs15763-G and rs1726745-A
Number of subjects: 507
Study 19769793 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype comprising alleles rs3781907-G, rs11235972-A, and rs1800849-T
Number of subjects: 507
Study 17558361 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy intervention for 14 weeks
Number of subjects: 15
Study 17558361 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 15
Study 17558361 — intervention group
Group type: COMPARATOR
Intervention: Final BBS scores comparison
Number of subjects: 15
Study 15675259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil 20 microg and intranasal midazolam 0.3 mg/kg
Number of subjects: 50
Study 15675259 — intervention group
Group type: COMPARATOR
Intervention: Intranasal ketamine 5 mg/kg and intranasal midazolam 0.3 mg/kg
Number of subjects: 50
Study 12495409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed current (HVPC) (100 microseconds, 150 V, 100 Hz) for 45 minutes, 3 times weekly, for 4 weeks
Number of subjects: 27
Study 12495409 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment for 45 minutes, 3 times weekly, for 4 weeks
Number of subjects: 27
Study 10524422 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost of 16 Gy
Number of subjects: 5569
Study 10524422 — intervention group
Group type: COMPARATOR
Intervention: No boost
Number of subjects: 5569
Study 10142126 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-provided case management services
Number of subjects: 0
Study 10142126 — intervention group
Group type: COMPARATOR
Intervention: Nonconsumer teams of case managers
Number of subjects: 0
Study 1718692 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 0.4 mg
Number of subjects: 12
Study 1718692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 12
Study 7057507 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with euflavine (spermicide)
Number of subjects: 36
Study 7057507 — intervention group
Group type: COMPARATOR
Intervention: Irrigation with sterile water
Number of subjects: 36
Study 31567357 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVI) irrigation
Number of subjects: 100
Study 31567357 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (NI)
Number of subjects: 100
Study 29369348 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (800 mg)
Number of subjects: 815
Study 29369348 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine-CR (200 mg BID)
Number of subjects: 815
Study 29369348 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (1200 mg)
Number of subjects: 815
Study 29369348 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine-CR (400 mg BID)
Number of subjects: 815
Study 27147223 — intervention group
Group type: EXPERIMENTAL
Intervention: Trampoline exercise + physiotherapy
Number of subjects: 12
Study 27147223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise + physiotherapy
Number of subjects: 12
Study 27147223 — intervention group
Group type: COMPARATOR
Intervention: Billiard (sham training) + physiotherapy
Number of subjects: 12
Study 25376394 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-labeling present prominently and consistently at main meals for 30 of the 36 weeks (Year 2)
Number of subjects: 240
Study 25376394 — intervention group
Group type: COMPARATOR
Intervention: No calorie-labeling (Year 1)
Number of subjects: 240
Study 23364045 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Function Improvement Exercises (3 times a week for a total of 24 times)
Number of subjects: 48
Study 23364045 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 19939369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sequential acidic and less‐acidic FSH
Number of subjects: 188
Study 19939369 — intervention group
Group type: COMPARATOR
Intervention: Less‐acidic FSH (recombinant FSH)
Number of subjects: 188
Study 19939369 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic FSH (human‐derived FSH)
Number of subjects: 188
Study 18024128 — intervention group
Group type: EXPERIMENTAL
Intervention: Short text of information
Number of subjects: 37
Study 18024128 — intervention group
Group type: EXPERIMENTAL
Intervention: Text read and discussed
Number of subjects: 37
Study 18024128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 37
Study 15332095 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated device (meibomian therapy with latent heat)
Number of subjects: 24
Study 15332095 — intervention group
Group type: COMPARATOR
Intervention: Inactivated device
Number of subjects: 24
Study 15332095 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 24
Study 14972792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer patients
Number of subjects: 0
Study 14972792 — intervention group
Group type: COMPARATOR
Intervention: Age matched controls
Number of subjects: 0
Study 9813877 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated oxygen deficit (AOD) measured at 1% treadmill gradient
Number of subjects: 9
Study 9813877 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated oxygen deficit (AOD) measured at 10.5% treadmill gradient
Number of subjects: 9
Study 9813877 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD estimated from linear fit of VO2 data
Number of subjects: 9
Study 9813877 — intervention group
Group type: EXPERIMENTAL
Intervention: AOD estimated from curvilinear fit of VO2 data
Number of subjects: 9
Study 9813877 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max and running economy
Number of subjects: 9
Study 8132436 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-30 mg daily)
Number of subjects: 50
Study 8132436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (200-400 mg daily)
Number of subjects: 50
Study 8132436 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine followed by Sulpiride
Number of subjects: 50
Study 8132436 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride followed by Paroxetine
Number of subjects: 50
Study 2782130 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 96
Study 2782130 — intervention group
Group type: COMPARATOR
Intervention: None alcohol consumption
Number of subjects: 96
Study 2782130 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensation seeking
Number of subjects: 96
Study 2782130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sensation seeking
Number of subjects: 96
Study 2782130 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol expectancy
Number of subjects: 96
Study 2782130 — intervention group
Group type: EXPERIMENTAL
Intervention: None alcohol expectancy
Number of subjects: 96
Study 803414 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 32
Study 803414 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32
Study 30711649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 or 10 mg/kg every 3 weeks
Number of subjects: 0
Study 30711649 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 0
Study 29142982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg
Number of subjects: 33
Study 29142982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 10 mg
Number of subjects: 33
Study 29142982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 20 mg
Number of subjects: 33
Study 29142982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 2.5 mg (multiple dose)
Number of subjects: 33
Study 29142982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide 5 mg (multiple dose)
Number of subjects: 33
Study 29142982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide (all doses)
Number of subjects: 33
Study 29142982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25956867 — intervention group
Group type: EXPERIMENTAL
Intervention: SIS myringoplasty
Number of subjects: 404
Study 25956867 — intervention group
Group type: COMPARATOR
Intervention: PTF myringoplasty
Number of subjects: 404
Study 23124935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab early
Number of subjects: 200
Study 23124935 — intervention group
Group type: COMPARATOR
Intervention: Rituximab late
Number of subjects: 200
Study 23124935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab early and late
Number of subjects: 200
Study 21490520 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 64
Study 21490520 — intervention group
Group type: COMPARATOR
Intervention: Single-location injection of local anesthetic (30 mL admixture of 1:1 lidocaine 2%/bupivacaine 0.5% with 1:200,000 epinephrine)
Number of subjects: 64
Study 18580399 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise (progressive resistance training)
Number of subjects: 30
Study 18580399 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study 16893438 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 2800
Study 16893438 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 2800
Study 16893438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2800
Study 15344445 — intervention group
Group type: EXPERIMENTAL
Intervention: Model built using the new approach to model optimisation
Number of subjects: 82
Study 15344445 — intervention group
Group type: COMPARATOR
Intervention: Previously published method for building 3D models
Number of subjects: 82
Study 15344445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both models used to investigate shape differences
Number of subjects: 82
Study 15344445 — intervention group
Group type: EXPERIMENTAL
Intervention: Model built using the new approach
Number of subjects: 82
Study 11014136 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatment recommendations for bite wounds
Number of subjects: 0
Study 9358138 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose inhaled budesonide (400 microg) plus theophylline (250 or 375 mg depending on body weight)
Number of subjects: 62
Study 9358138 — intervention group
Group type: COMPARATOR
Intervention: High-dose inhaled budesonide (800 microg)
Number of subjects: 62
Study 9358138 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (low-dose budesonide plus theophylline and high-dose budesonide)
Number of subjects: 62
Study 8199605 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of zinc gluconate daily
Number of subjects: 35
Study 8199605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3676055 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% etidocaine with adrenaline (group Ea)
Number of subjects: 27
Study 3676055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plain (group Bp)
Number of subjects: 27
Study 3676055 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline (group Ba)
Number of subjects: 27
Study 3676055 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 27
Study 31845142 — intervention group
Group type: EXPERIMENTAL
Intervention: Image fusion (using CTA and CTC, n = 40)
Number of subjects: 80
Study 31845142 — intervention group
Group type: COMPARATOR
Intervention: Control (without CTA and CTC reconstruction)
Number of subjects: 80
Study 30458930 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-401 10 mg
Number of subjects: 15
Study 30458930 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-401 60 mg
Number of subjects: 15
Study 30458930 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-401 150 mg
Number of subjects: 15
Study 30458930 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-401 (various doses)
Number of subjects: 15
Study 30458930 — intervention group
Group type: EXPERIMENTAL
Intervention: ME-401 once daily 60 mg
Number of subjects: 15
Study 28190787 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat up to 2.5 mg 3 times a day
Number of subjects: 443
Study 26618449 — intervention group
Group type: EXPERIMENTAL
Intervention: TAE + TVRC(LDSI)
Number of subjects: 58
Study 26618449 — intervention group
Group type: COMPARATOR
Intervention: TAE + TVRC
Number of subjects: 58
Study 22682093 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied around the knee joint during maximal voluntary contraction measurement after vibration.
Number of subjects: 0
Study 22682093 — intervention group
Group type: COMPARATOR
Intervention: Non-taping condition (no Kinesiology tape applied).
Number of subjects: 0
Study 21682813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer walking plus motivational interviewing (PWMI) program
Number of subjects: 64
Study 21682813 — intervention group
Group type: COMPARATOR
Intervention: Control group (leaflet only)
Number of subjects: 64
Study 19538718 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Disease Modifying Antirheumatic Drug therapy
Number of subjects: 810
Study 19538718 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy methotrexate
Number of subjects: 810
Study 19538718 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Modifying Antirheumatic Drug of various intensities
Number of subjects: 810
Study 19538718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs, hydroxychloroquine, and a single dose of corticosteroids
Number of subjects: 810
Study 16951642 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI) for 4 months
Number of subjects: 274
Study 16951642 — intervention group
Group type: COMPARATOR
Intervention: Control arm (immediate change to optimized antiretroviral regimen)
Number of subjects: 274
Study 16951642 — intervention group
Group type: EXPERIMENTAL
Intervention: STI
Number of subjects: 274
Study 15305348 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia decision aid (IMDA)
Number of subjects: 201
Study 15305348 — intervention group
Group type: COMPARATOR
Intervention: Control group (video and information leaflet)
Number of subjects: 201
Study 11776481 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg, 4 times daily for 2 consecutive days
Number of subjects: 201
Study 11776481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 9305557 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastograph (TEG) analysis in morbidly obese patients
Number of subjects: 26
Study 9305557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonoclot analysis in morbidly obese patients
Number of subjects: 26
Study 9305557 — intervention group
Group type: COMPARATOR
Intervention: Lean controls (N=26)
Number of subjects: 26
Study 8496384 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised systems for warfarin control
Number of subjects: 186
Study 8496384 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised dosage programs
Number of subjects: 186
Study 8496384 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing method by experienced medical staff
Number of subjects: 186
Study 3100146 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (53 percent of calories)
Number of subjects: 15
Study 3100146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-based diet (55 percent of calories)
Number of subjects: 15
Study 3100146 — intervention group
Group type: COMPARATOR
Intervention: Control group (malnourished patients without COPD)
Number of subjects: 15
Study 3100146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (CB and FB)
Number of subjects: 15
Study 3100146 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-based diet (CB)
Number of subjects: 15
Study 29434272 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Inguinal Microscope-Assisted Varicocelectomy (MIMV)
Number of subjects: 3565
Study 29434272 — intervention group
Group type: COMPARATOR
Intervention: Conventional Microsurgical Subinguinal Varicocelectomy (CMSV)
Number of subjects: 3565
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic decompressive craniectomy
Number of subjects: 336
Study 26727957 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic decompressive craniectomy
Number of subjects: 336
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured by EQ-5D
Number of subjects: 336
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 336
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 336
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure control
Number of subjects: 336
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure control
Number of subjects: 336
Study 26727957 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of salvage craniectomy in craniotomy patients
Number of subjects: 336
Study 24880749 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (500 mg, twice a day)
Number of subjects: 38
Study 24880749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22493350 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGPH20 (pegylated PH20 hyaluronidase)
Number of subjects: 0
Study 20627015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy catheter
Number of subjects: 202
Study 18841078 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Stretch
Number of subjects: 20
Study 18841078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic Stretch
Number of subjects: 20
Study 18841078 — intervention group
Group type: COMPARATOR
Intervention: No Stretch
Number of subjects: 20
Study 15596954 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control using antiarrhythmic drugs
Number of subjects: 5175
Study 15596954 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 5175
Study 15596954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus rhythm presence
Number of subjects: 5175
Study 12527962 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) users during days 15-28
Number of subjects: 15
Study 12527962 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive (OC) users during days 1-14
Number of subjects: 15